Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 8 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 13 patents granted in the last 365 days
BEIGENE, LTD. has 8 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 8 examiners and 8 art units, showing a fully dispersed prosecution profile across the reported assignments.
WARD, PAUL V is the busiest examiner with 1 pending matter. The absence of examiner or art-unit concentration makes centralized consistency important, especially for recurring biotechnology terminology, while substantive response planning remains matter-specific.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 3 (38%) |
| Multi-statute (no §101) | 5 (62%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WARD, PAUL V | 1 | 83.2% | -12.2% |
| ISMAIL, REHANA | 1 | 76.2% | +34.8% |
| KOSACK, JOSEPH R | 1 | 74.8% | -6.1% |
| REILLY, SOPHIA JANE | 1 | 60.0% | +49.4% |
| SHTERENGARTS, SAMANTHA L | 1 | 79.5% | +8.0% |
| YOO, SUN JAE | 1 | 71.2% | +0.3% |
| TOWNSLEY, SARA ELIZABETH | 1 | 25.6% | +48.2% |
| CREWS, JARET JAMES | 1 | 43.9% | +71.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19011372 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | WARD, PAUL V | — |
| 18926544 | Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors | KOSACK, JOSEPH R | — |
| 18894069 | BCL-XL INHIBITORS | REILLY, SOPHIA JANE | — |
| 18761919 | Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors | YOO, SUN JAE | — |
| 18016292 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | TOWNSLEY, SARA ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18934390 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | ISMAIL, REHANA | — |
| 18894069 | BCL-XL INHIBITORS | REILLY, SOPHIA JANE | — |
| 18016292 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | TOWNSLEY, SARA ELIZABETH | — |
| 17612056 | AMIDE-SUBSTITUTED IMIDAZO COMPOUNDS AS SELECTIVE INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASES | CREWS, JARET JAMES | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1625 | 1 |
| 3991 | 1 |
| 1627 | 1 |
| 1623 | 1 |
| 1621 | 1 |
| 1629 | 1 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19011372 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | WARD, PAUL V | 1622 | §102§103§112 | Non-Final OA | — | Pending | Jan 06, 2025 |
| 18934390 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | ISMAIL, REHANA | 1625 | §112 | Non-Final OA | — | Pending | Nov 01, 2024 |
| 18926544 | Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors | KOSACK, JOSEPH R | 3991 | §102§112 | Non-Final OA | — | Pending | Oct 25, 2024 |
| 18894069 | BCL-XL INHIBITORS | REILLY, SOPHIA JANE | 1627 | §103§112 | Non-Final OA | — | Pending | Sep 24, 2024 |
| 18825776 | 4-(Aminomethyl)-6-(1-Methyl-1H-Pyrazol-4-YL)Isoquinolin-1(2H)-One Derivatives as MTA-Cooperative Inhibitors of PRMT5 | SHTERENGARTS, SAMANTHA L | 1623 | §112 | Non-Final OA | — | Pending | Sep 05, 2024 |
| 18761919 | Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors | YOO, SUN JAE | 1621 | §102§112 | Non-Final OA | — | Pending | Jul 02, 2024 |
| 18016292 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | TOWNSLEY, SARA ELIZABETH | 1629 | §102§103§112 | Final Rejection | — | Pending | Jan 13, 2023 |
| 17612056 | AMIDE-SUBSTITUTED IMIDAZO COMPOUNDS AS SELECTIVE INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASES | CREWS, JARET JAMES | 1691 | §112 | Non-Final OA | — | Pending | Nov 17, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBEIGENE, LTD. has 8 pending office actions as of October 2026, spread across 8 art units and 8 examiners.
Paul V Ward has the most, with 1 of BEIGENE, LTD.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
